Aquestive Therapeutics
AQST
180 hedge funds and large institutions have $299M invested in Aquestive Therapeutics in 2026 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 56 increasing their positions, 47 reducing their positions, and 44 closing their positions.
347% more call options, than puts
Call options by funds: $9.58M | Put options by funds: $2.14M
19% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 47
11% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 44
2% more funds holding
Funds holding: 177 → 180 (+3)
0.3% less ownership
Funds ownership: 59.21% → 58.91% (-0.3%)
36% less capital invested
Capital invested by funds: $467M → $299M (-$168M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$7.83M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$4.86M |
| 3 |
RI
RTW Investments
New York
|
+$4.77M |
| 4 |
SCM
Sio Capital Management
New York
|
+$3.77M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$17M |
| 2 |
HF
HRT Financial
New York
|
-$6.43M |
| 3 |
Millennium Management
New York
|
-$6.13M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$5.23M |
| 5 |
PA
Perceptive Advisors
New York
|
-$4.83M |
AQST Hedge Fund Activity: Q1 2026 in Review
180 of the 8,177 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q1 2026, worth a combined $299M — down 36% from $467M a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new AQST positions and 44 closed out — a net gain of 5 holders — while 56 added to existing stakes and 47 trimmed.
The largest buyer was Balyasny Asset Management, adding an estimated $7.83M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $17M sold.
- 180 institutional investors held Aquestive Therapeutics (AQST) as of Q1 2026, up from 177 in Q4 2025.
- Funds reported $299M of Aquestive Therapeutics stock for Q1 2026, down 36% quarter-over-quarter.
- 49 funds opened new Aquestive Therapeutics positions in Q1 2026 and 44 closed out, a net change of +5 holders.
- The largest Aquestive Therapeutics buyer in Q1 2026 was Balyasny Asset Management, an estimated $7.83M added.
- The largest Aquestive Therapeutics seller in Q1 2026 was EcoR1 Capital, an estimated $17M sold.
Based on aggregated 13F filings for Q1 2026.